Eli Lilly has achieved an extraordinary medical breakthrough with ZEPBOUND (tirzepatide), establishing new therapeutic standards within sleep disorder healthcare delivery. The landmark FDA approves ZEPBOUND for obstructive sleep apnea approval in December 2024 introduces the first medication specifically formulated to combat this widespread sleep-related respiratory disorder. This regulatory...